Optimal Revascularization Time in Transient STEMI

Patients admitted with transient ST elevation MI and later normalize completely (symptimos disappear before being treated) are those we normally say are “undergoing a non-ST elevation MI”. This is complex, because revascularization time remains nuclear, as is whether to treat them as STEMI or non-STEMI patients.

The aim of this study was to determine the effects of an immediate strategy, compared against a differed strategy, quantifying infarct size with cardiac magnetic resonance.

 

The study randomized 142 patients with transient ST elevation MI to immediate (as if it were primary PCI in persistent STEMI patients) mean 0.3 hours vs. invasive differed strategy (as non-STEMI patients) with mean 22.7 hours.



Read also: The Ten Commandments for the Fourth Universal Definition of Infarction.


Infarction size measured by CMR at day 4 after the event was small and similar between strategies.

 

Neither were there differences in terms of major cardiac events, a combination of death, reinfarction or revascularization at 30 days (2.9% vs. 2.8%, p=1.00).


Read also: Are Aortic Stenosis and Kidney Dysfunction Associated?


Only 4 patients in the deferred group (5.6%) required emergency intervention given their signs and symptoms while waiting the angiography.

 

Conclusion

Globally, infarct size in patients presenting transient ST elevation MI is small and revascularization strategy, whether immediate or differed, has no influence. Hard events at short term were low and similar between the groups.

 

Original title: Timing of revascularization in patients with transient ST-segment elevation myocardial infarction: a randomized clinical trial.

Reference: Jorrit S. Lemkes et al. European Heart Journal (2019) 40, 283–291.

 

Infarto-elevacion-transitoria-st


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...

ACC 2026 | STEMI-Door To Unload: Unloading with Impella before PCI did not reduce infarct size in anterior STEMI

Anterior ST-segment elevation myocardial infarction (STEMI) remains associated with a high incidence of heart failure and mortality, even in the era of early reperfusion....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...